Metsera Inc. (NASDAQ:MTSR) Given Average Rating of “Hold” by Analysts

Shares of Metsera Inc. (NASDAQ:MTSR) have received an average rating of “Hold” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $55.75.

Several brokerages recently commented on MTSR. Bank of America lifted their target price on shares of Metsera from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Metsera in a report on Wednesday, September 3rd. Leerink Partnrs downgraded shares of Metsera from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 24th. Leerink Partners restated a “market perform” rating and set a $57.00 price objective (down previously from $77.00) on shares of Metsera in a report on Wednesday, September 24th. Finally, Wall Street Zen upgraded shares of Metsera from a “sell” rating to a “hold” rating in a report on Wednesday, October 1st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MTSR. Bank of New York Mellon Corp bought a new position in shares of Metsera during the 1st quarter worth about $884,000. New York State Common Retirement Fund bought a new position in shares of Metsera during the 1st quarter worth about $131,000. Alphabet Inc. bought a new position in shares of Metsera during the 1st quarter worth about $135,059,000. Massachusetts Financial Services Co. MA bought a new position in shares of Metsera during the 1st quarter worth about $13,111,000. Finally, Jennison Associates LLC bought a new position in shares of Metsera during the 1st quarter worth about $9,679,000.

Metsera Stock Up 0.2%

MTSR stock opened at $52.99 on Friday. Metsera has a 1 year low of $12.30 and a 1 year high of $54.47. The company has a fifty day simple moving average of $41.37 and a 200 day simple moving average of $32.68.

Metsera (NASDAQ:MTSR) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.